Sign inThe company reported a narrower net loss, lower cash operating expense guidance, and a new early discovery milestone in its neuroscience collaboration with Roche and Genentech.
SEC filing
VEPPANU won FDA approval and was licensed to Rigel Pharmaceuticals, while Arvinas outlined data timelines for three Phase 1 programs and cash runway into second-half 2028.
SEC filing
Revuforj and Niktimvo both posted double-digit year-over-year net revenue growth as Syndax laid out new trial timelines for its expanded pipeline.
SEC filing
The company says the rolling NDA submission stays on track for the second half of 2026, with a U.S. launch planned for early 2027 if approved.
SEC filing
OnKure Therapeutics said it is no longer subject to a rule limiting how much stock it can sell under its existing $100 million at-the-market program with Leerink Partners.
SEC filing
Larimar says FDA aligned on a rolling BLA path for nomlabofusp in Friedreich's ataxia and expects to start a global confirmatory Phase 3 study in the third quarter of 2026.
SEC filing
Arrowhead reported topline Phase 3 results for plozasiran in severe hypertriglyceridemia and disclosed a PNPLA3 licensing deal with Madrigal worth up to $975 million in milestones.
SEC filing
WAKIX net revenue rose 30% to $261.3 million in Q2 2026 as Harmony released single ascending dose data for orexin-2 agonist BP-205 and reaffirmed full-year guidance.
SEC filing
OptimUM-02 met its progression-free survival goal in metastatic uveal melanoma as IDEAYA files an NDA under FDA's real-time review program, backed by $1.24 billion in cash.
SEC filing
Pfizer lifted the midpoint of its full-year revenue guidance while reaffirming adjusted EPS guidance, which factors in costs tied to its Innovent Biologics licensing deal.
SEC filing
FILSPARI's FSGS launch and IgAN demand drove sales growth as pegtibatinase enrollment continues and civorebrutinib joins the pipeline.
SEC filing
The Nasdaq-listed vector-borne disease drugmaker sold shares and warrants at $1.74 per share, with H.C. Wainwright as placement agent.
SEC filing
Cumberland Pharmaceuticals reported new Phase 2 results for ifetroban in Duchenne muscular dystrophy and cancer metastasis prevention alongside second-quarter 2026 results following its $100 million Apotex transaction.
SEC filing
At its August 3, 2026 annual meeting, Theriva Biologics shareholders approved six proposals, including an increase in shares available under its 2020 Stock Incentive Plan.
SEC filing
The clinical-stage biotech hired the former Eli Lilly insulin executive effective July 31, 2026, and granted her 430,000 inducement stock options.
SEC filing
The company said its Phase 2 trial of PIKTOR in endometrial cancer remains on track for year-end topline results, with breast cancer data expected in 2027.
SEC filing
Dianthus disclosed a 75% response rate in an interim look at Part A of its Phase 3 CIDP trial and said its Phase 3 gMG trial began in June, alongside second-quarter results dated August 4, 2026.
SEC filing
Amgen widened its MariTide Phase 3 program, dropped AMG 513, and continued its fight with the FDA over pulling TAVNEOS, while reporting second-quarter results.
SEC filing
All six director nominees were reelected and shareholders backed a 200,000-share expansion of the company's incentive plan, per an August 4 8-K filing.
SEC filing
Seres registered 103,520 shares for BMR-Sidney at $4.83 each, worth $500,001.60, as partial payment for ending its Sidney Research Campus lease.
SEC filing
The company reported second-quarter 2026 results alongside progress on its AATD, PKU, and sickle cell programs, with $1.2 billion in cash guided to last into mid-2029.
SEC filing
OnKure said OKI-355 and OKI-345 remain in IND-enabling work with FDA submissions planned for the first half of 2027, and cash of $176.4 million is expected to fund operations into 2029.
SEC filing
The oncology and hematology company licensed the PROTAC breast cancer drug from Arvinas and Pfizer and expects U.S. launch in mid-August, while its R289 MDS trial stays on track for second-half 2026 dose selection.
SEC filing
Richard E. Uihlein swapped notes across five credit lines for 34,376,167 shares, cutting Galectin's debt load and lifting his voting stake to about 49.3%.
SEC filing
Pacira closed its iovera° divestiture on July 31, advanced its PCRX-201 gene therapy program, and trimmed full-year revenue guidance to reflect the sale.
SEC filing
Nuvectis says partner Haisco's China approval of ciprocopan for untreated PNH patients validates the drug as it plans a U.S. IND submission in the fourth quarter.
SEC filing
The appointment took effect July 31, 2026, elevating a longtime executive who has been with the company since 2017.
SEC filing
The company raised its 2026 revenue and EPS guidance ranges after second quarter results driven by CAG Diagnostics gains and IDEXX inVue Dx placements.
SEC filing
A $6.8 billion acquisition drove a GAAP loss per share of $0.54, while Merck lifted its 2026 sales guidance and reported new approvals and trial data across oncology, HIV and cardiometabolic programs.
SEC filing
Lipocine plans an FDA guidance meeting in the third quarter of 2026 and has started a new placebo-controlled trial for LPCN 1154 after a post hoc analysis flagged one site's data.
SEC filing
The company reaffirmed full-year 2026 revenue guidance and flagged upcoming FDA decisions for DTX401 and UX111 alongside pivotal Phase 3 data for GTX-102 in Angelman syndrome.
SEC filing
The company reported its eighth straight quarter of sequential product revenue growth and disclosed new regulatory and supply milestones for ANKTIVA.
SEC filing
Second-quarter net revenue of $53.1 million drove net income of $20.1 million, and the company said cash on hand plus product sales should carry it to cash flow break-even by year-end 2026.
SEC filing
The Cambridge biotech will use the proceeds to advance CMP-002, its SYNGAP1-related disorder therapy, following Australian clearance to begin a Phase 1/2 trial.
SEC filing
A Form D filed August 4, 2026 shows Jasper Therapeutics sold $131,999,611 in equity securities to 40 investors under a Rule 506(b) exemption.
SEC filing
Tyra says initial SURF302 data are expected in September 2026, while a BEACH301 achondroplasia readout slips to end of Q1 2027 as a fifth dose level is added.
SEC filing
Tyra amended its sales agreement with TD Cowen on August 4, 2026, after fully using a prior $150 million facility, raising the ceiling on shares it can sell through the program.
SEC filing
Spyre says both antibodies hit primary and secondary endpoints in ulcerative colitis, while three SKYWAY sub-studies finished enrollment ahead of schedule.
SEC filing
The company posted a GAAP diluted loss of $8.45 per share tied to acquisition charges while raising full-year product sales guidance.
SEC filing
The company also completed Phase 2 enrollment in its remlifanserin Alzheimer's psychosis program and won FDA Fast Track designation, with topline data expected in September to October 2026.
SEC filing
The company said Phase 2a monotherapy data on OD-001 will be presented in October, with a combination trial and a Phase 2b trial slated to start later in 2026, backed by $433.1 million in cash.
SEC filing